Loading organizations...

Kerecis is a technology company.
Kerecis develops and manufactures patented medical devices for soft tissue regeneration, leveraging proprietary technology based on decellularized intact fish skin. Products, derived from Atlantic cod skin rich in Omega3 fatty acids, facilitate healing in chronic wounds, surgical reconstruction, and burn treatment. These solutions hold regulatory approvals in major global markets.
The company originated in 2007 with founder Fertram Sigurjonsson, initiating medical device projects. Combining his chemical engineering background and Icelandic fishing community insights, Sigurjonsson conceived using fish skin for tissue repair. He assembled a founding team including medical doctors Baldur Tumi Baldursson and Hilmar Kjartansson, alongside legal and scientific advisors.
Kerecis products serve healthcare providers in hospitals, clinics, and veterinary settings for diverse tissue injuries. The company envisions pioneering fish skin and its fatty acids in cellular therapy, advancing global regenerative medicine. Their mission is to improve patient outcomes with unique, biologically-derived solutions for complex tissue repair.
Kerecis has raised $143.0M across 6 funding rounds.
Kerecis has raised $143.0M in total across 6 funding rounds.
Kerecis has raised $143.0M in total across 6 funding rounds.
Kerecis's investors include Niklas Sjoblom, BRU, Emerson Collective, LSV, Silicon Valley Bank, Julie Betts, Crowberry Capital, 1924, Capital, Hradfrystihusid-Gunnvor, Klofningur, NSA Ventures.
Kerecis is an Icelandic medical-technology company that develops and manufactures patented intact fish‑skin grafts and related regenerative products used to accelerate healing of acute and chronic wounds and to support soft‑tissue regeneration in surgical indications.[2][8]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / MedTech Landscape
Quick Take & Future Outlook
Quick take: Kerecis combines a distinctive biologic (intact fish skin with omega‑3 properties), a sustainability narrative, and validated clinical adoption to address pressing wound‑care needs; its future hinges on translating clinical evidence and reimbursement wins into broader surgical application and scalable global distribution.[6][7][5]
Kerecis has raised $143.0M across 6 funding rounds. Most recently, it raised $100.0M Debt / Other Equity / Series D Extension in August 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2022 | $100.0M Debt / Other Equity / Series D Extension | Niklas Sjoblom | BRU, Emerson Collective, LSV, Silicon Valley Bank |
| Aug 27, 2020 | $21.0M Debt / Other Equity | Julie Betts | |
| Jun 13, 2019 | $16.0M Series C | ||
| Jan 4, 2018 | $3.0M Other Equity | ||
| Feb 1, 2014 | $2.0M Series A | Crowberry Capital, 1924, Capital, Hradfrystihusid-Gunnvor, Klofningur, NSA Ventures, Omega Venture Partners, Skogur | |
| Apr 26, 2013 | $1.0M Series A |